Duality Biotherapeutics, Inc. risk profile
43 Elevated one input has moved against it
Measured 16 September 2026 from 4ZB's filed statements. Recomputed nightly.
43 (Elevated), driven by Market expectation at 80, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Stable | Drawdown from the 52-week high — 64.2% |
| Operating pressure | 43 | Elevated | Easing | Costs outgrowing revenue — +12.2 percentage points |
| Cash conversion | 23 | Normal | Worsening | Capital spending against operating cash — 0.07x |
| Leverage and coverage | 38 | Normal | Easing | Interest cover — -2,133.31x |
| Competitive position | 44 | Elevated | Stable | Operating-margin gap against peers — -27.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 34Johnson & Johnson 39Abbvie Inc 58Merck & Co Inc 35Unitedhealth Group Inc 50Roche Holding AG 36Novartis AG 33Novartis AG 30Astrazeneca plc 34Thermo Fisher Scientific Inc 47AMGEN Inc 48Novo Nordisk A/S 23
Financials, valuation and price history for Duality Biotherapeutics, Inc.